Literature DB >> 9930748

Quantification of axonal damage in traumatic brain injury: affinity purification and characterization of cerebrospinal fluid tau proteins.

F P Zemlan1, W S Rosenberg, P A Luebbe, T A Campbell, G E Dean, N E Weiner, J A Cohen, R A Rudick, D Woo.   

Abstract

Diffuse axonal injury is a primary feature of head trauma and is one of the most frequent causes of mortality and morbidity. Diffuse axonal injury is microscopic in nature and difficult or impossible to detect with imaging techniques. The objective of the present study was to determine whether axonal injury in head trauma patients could be quantified by measuring levels of CSF tau proteins. Tau proteins are structural microtubule binding proteins primarily localized in the axonal compartment of neurons. Monoclonal antibodies recognizing the form of tau found in the CSF of head trauma patients were developed by differential CSF hybridoma screening using CSF from head trauma and control patients. Clones positive for head trauma CSF tau proteins were used to characterize this form of tau and for ELISA development. Using the developed ELISA, CSF tau levels were elevated >1,000-fold in head trauma patients (mean, 1,519 ng/ml of CSF) when compared with patients with multiple sclerosis (mean, 0.014 ng/ml of CSF; p < 0.001), normal pressure hydrocephalus (nondetectable CSF tau), neurologic controls (mean, 0.031 ng/ml of CSF; p < 0.001), or nonneurologic controls (nondetectable CSF tau; p < 0.001). In head trauma, a relationship between clinical improvement and decreased CSF tau levels was observed. These data suggest that CSF tau levels may prove a clinically useful assay for quantifying the axonal injury associated with head trauma and monitoring efficacy of neuroprotective agents. Affinity purification of CSF tau from head trauma patients indicated a uniform cleavage of approximately 18 kDa from all six tau isoforms, reducing their apparent molecular sizes to 30-50 kDa. These cleaved forms of CSF tau consisted of the interior portion of the tau sequence, including the microtubule binding domain, as judged by cyanogen bromide digestion. Consistent with these data, CSF cleaved tau bound taxol-polymerized microtubules, indicating a functionally intact microtubule binding domain. Furthermore, epitope mapping studies suggested that CSF cleaved tau proteins consist of the interior portion of the tau sequence with cleavage at both N and C terminals.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9930748     DOI: 10.1046/j.1471-4159.1999.0720741.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  45 in total

1.  Both total and phosphorylated tau are increased in Alzheimer's disease.

Authors:  M Sjögren; P Davidsson; M Tullberg; L Minthon; A Wallin; C Wikkelso; A K Granérus; H Vanderstichele; E Vanmechelen; K Blennow
Journal:  J Neurol Neurosurg Psychiatry       Date:  2001-05       Impact factor: 10.154

Review 2.  Blood-based diagnostics of traumatic brain injuries.

Authors:  Stefania Mondello; Uwe Muller; Andreas Jeromin; Jackson Streeter; Ronald L Hayes; Kevin K W Wang
Journal:  Expert Rev Mol Diagn       Date:  2011-01       Impact factor: 5.225

3.  Plasma tau as a window to the brain-negative associations with brain volume and memory function in mild cognitive impairment and early Alzheimer's disease.

Authors:  Ming-Jang Chiu; Ya-Fang Chen; Ta-Fu Chen; Shieh-Yueh Yang; Fan-Pei Gloria Yang; Tien-Wen Tseng; Jen-Jie Chieh; Jia-Chun Rare Chen; Kai-Yuan Tzen; Mau-Sun Hua; Herng-Er Horng
Journal:  Hum Brain Mapp       Date:  2013-10-15       Impact factor: 5.038

4.  Novel human neuronal tau model exhibiting neurofibrillary tangles and transcellular propagation.

Authors:  Patrick Reilly; Charisse N Winston; Kelsey R Baron; Margarita Trejo; Edward M Rockenstein; Johnny C Akers; Najla Kfoury; Marc Diamond; Eliezer Masliah; Robert A Rissman; Shauna H Yuan
Journal:  Neurobiol Dis       Date:  2017-06-10       Impact factor: 5.996

5.  Problems associated with biological markers of Alzheimer's disease.

Authors:  H J Frey; K M Mattila; M A Korolainen; T Pirttilä
Journal:  Neurochem Res       Date:  2005-12       Impact factor: 3.996

Review 6.  Stratification of patients is the way to go to develop neuroprotective/disease-modifying drugs for Alzheimer's disease.

Authors:  Khalid Iqbal; M Omar Chohan; Inge Grundke-Iqbal
Journal:  J Alzheimers Dis       Date:  2008-10       Impact factor: 4.472

7.  Plasma 24S-hydroxycholesterol and other oxysterols in acute closed head injury.

Authors:  Myron F Weiner; Gloria L Vega; Ramon Diaz-Arrastia; Carol Moore; Christopher Madden; Anne Hudak; Dieter Lütjohann
Journal:  Brain Inj       Date:  2008-07       Impact factor: 2.311

8.  Multiple proteins implicated in neurodegenerative diseases accumulate in axons after brain trauma in humans.

Authors:  Kunihiro Uryu; Xiao-Han Chen; Dan Martinez; Kevin D Browne; Victoria E Johnson; David I Graham; Virginia M-Y Lee; John Q Trojanowski; Douglas H Smith
Journal:  Exp Neurol       Date:  2007-07-10       Impact factor: 5.330

9.  Ubiquitin fusion degradation protein 1 as a blood marker for the early diagnosis of ischemic stroke.

Authors:  Laure Allard; Natacha Turck; Pierre R Burkhard; Nadia Walter; Anna Rosell; Marianne Gex-Fabry; Denis F Hochstrasser; Joan Montaner; Jean-Charles Sanchez
Journal:  Biomark Insights       Date:  2007-04-19

Review 10.  Chronic traumatic encephalopathy-integration of canonical traumatic brain injury secondary injury mechanisms with tau pathology.

Authors:  Jacqueline R Kulbe; Edward D Hall
Journal:  Prog Neurobiol       Date:  2017-08-26       Impact factor: 11.685

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.